BioNTech SE BNTX
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -7.38%
- 1 year
- -15.76%
- Open
- 89.22
- Prev close
- 89.13
- Mkt cap
- 22.15B
- Vol
- 631.91K
- Avg vol
- 1.26M
- EPS
- -7.83
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 87.47
- High
- 90.32
- Forward P/E
- -16.31
- Beta
- 1.25
- Short ratio
- 2.35
- Inst. own
- 19.75%
- Dividend
- 0.00
- Ex-div date
- Jun 1, 2022
- Earnings
- Nov 3, 2026
- 50-d avg
- 97.70
- 200-d avg
- 97.20
- 1y target
- 116.66
5D chart
Signals (158)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:20 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 2:20 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:15 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 2:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:55 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 1:15 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 1:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:45 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:45 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:25 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:25 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 11:10 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:55 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:15 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:10 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:05 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:05 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:45 AM | 2 days ago |
| RSI: Overbought | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:05 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:25 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:15 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:10 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:50 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 11:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:15 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:10 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:25 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:20 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:20 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:40 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 5 days ago |
| RSI: Oversold | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 6 days ago |
| RSI: Oversold | Oct 26, 3:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:40 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 12:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:15 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
4 days ago 247wallst.com
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
Shrugging off a valuation downgrade, Moderna (NASDAQ:MRNA | MRNA Price Prediction) is climbing as investors weigh strong cancer vaccine data against a share price that already reflects big…
6 days ago investopedia.com
Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next
Moderna's stock has taken a big hit that could signal the end of this year's cancer vaccine-driven rally. It may not be too late to play the forces behind its rise.
6 days ago benzinga.com
BioNTech Evaluates Next Steps as Breast Cancer Drug Shows Limited Patient Benefit
BioNTech and DualityBio report modest Phase 3 breast cancer survival gains alongside higher lung toxicity, limiting overall patient benefit.
6 days ago 247wallst.com
Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady
A closely tracked personalized melanoma vaccine met its main goal. Its effect on distant spread came in far smaller than an earlier study suggested in a late-stage trial.
6 days ago globenewswire.com
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
MAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the…
1 week ago globenewswire.com
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
MAINZ, Germany, and PRINCETON, USA, October 25, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced first data from the global Phase 2…
1 week ago 247wallst.com
Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher
A late-stage melanoma vaccine report that was posted online and quickly pulled is driving a violent repricing in Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, even though its findings looked…
1 week ago reuters.com
BioNTech, Gilead to test drug combination in advanced breast cancer trial
BioNTech, Gilead to test drug combination in advanced breast cancer trial
-
1 week ago benzinga.com
BioNTech Enters Clinical Trial Collaboration And Supply Agreement With Gilead Sciences To Evaluate Pumitamig In Combination With Sacituzumab Govitecan As First-Line Treatment For Patients With Locally Advanced Or Metastatic PD-L1 Low Or Negative Triple-negative Breast Cancer
Pumitamig is an investigational bispecific immunomodulator designed to cooperatively bind to PD-L1 and VEGF-A that is being jointly developed by BioNTech and Bristol Myers Squibb ("BMS").ROSETTA…
1 week ago globenewswire.com
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
MAINZ, Germany, October 22, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced a clinical trial collaboration and supply agreement with Gilead Sciences Inc. (“Gilead”) to evaluate…
1 week ago globenewswire.com
BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026
MAINZ, Germany, October 20, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2026 on Tuesday, November 3,…
-
1 week ago benzinga.com
BioNTech To Present New Clinical Data From Its Late-Stage Oncology Pipeline With 16 Abstracts At European Society For Medical Oncology, October 23–27; Key Oral Presentations Will Focus On Clinical Data For Pumitamig Plus Docetaxel In Second-Line Metastatic Non-Small Cell Lung Cancer
Late-breaking oral presentation will feature first data from the global ROSETTA Lung-107 Phase 2 clinical trial evaluating pumitamig, a PD-L1×VEGF-A bispecific immunomodulator, plus docetaxel in…
1 week ago globenewswire.com
BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
MAINZ, Germany, October 19, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data from its late-stage oncology pipeline with 16 abstracts spanning the…
2 weeks ago fool.com
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?
BioNTech needs new products to kickstart sales and earnings growth. But two of the company's candidates have experienced setbacks recently.
2 weeks ago fool.com
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline
A 16.6 billion euro cash balance gives BioNTech room to fund trials, partnerships, and a $1 billion share repurchase program. With 14 pivotal trials underway, including seven for pumitamig,…
2 weeks ago defenseworld.net
Reviewing MiMedx Group (NASDAQ:MDXG) and BioNTech (NASDAQ:BNTX)
BioNTech (NASDAQ: BNTX - Get Free Report) and MiMedx Group (NASDAQ: MDXG - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on…
2 weeks ago 247wallst.com
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Profit taking is hitting one of biotech's hottest trades, and the selling is landing heaviest on the stock that ran the furthest. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is down 10% to…
2 weeks ago 247wallst.com
Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher
Healthcare is drawing fresh buying as money moves away from the market's popular technology trade, and one messenger RNA (mRNA) name is pulling well ahead of the pack. Moderna (NASDAQ:MRNA | MRNA…
2 weeks ago prnewswire.com
BioNTech Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into BioNTech (BNTX)
BioNTech investors absorbed a 7.13% loss when the AHEAD-MERIT trial of BNT113 missed its progression-free survival primary endpoint. An investigation is underway into whether the Company's statements…
-
2 weeks ago benzinga.com
Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $132
Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $136 to $132.
2 weeks ago benzinga.com
Why Is BioNTech Stock Falling Tuesday?
BioNTech stock drops over 5% as BNT113 mRNA cancer trial misses PFS endpoint. Focus shifts to overall survival in HPV16+ HNSCC study.
2 weeks ago benzinga.com
Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. futures mixed; Syndax plunged 17% after its lung fibrosis trial missed its endpoint. Zhibao, Chaince, Six Flags and tech stocks also fell premarket.
-
2 weeks ago benzinga.com
BioNTech Reports AHEAD-MERIT Phase 2/3 Clinical Trial Did Not Meet First Dual Primary Endpoint Of Progression-Free Survival For mRNA Cancer Immunotherapy Candidate BNT113 Plus Pembrolizumab Compared With Pembrolizumab Alone
AHEAD-MERIT Phase 2/3 clinical trial did not meet its first dual primary endpoint of progression-free survival for the mRNA cancer immunotherapy candidate BNT113 plus pembrolizumab compared with…
2 weeks ago globenewswire.com
BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
MAINZ, Germany, October 13, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced the first topline results from the AHEAD-MERIT Phase 2/3 clinical trial (NCT04534205) for…
2 weeks ago fool.com
Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick?
Moderna's market cap has soared on positive results for its mRNA cancer vaccine. Meanwhile, BioNTech has floundered after disappointing clinical results.
2 weeks ago zacks.com
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research funding.
3 weeks ago defenseworld.net
BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 36,209 Shares
BioNTech SE Sponsored ADR (NASDAQ: BNTX - Get Free Report) CEO Ugur Sahin sold 36,209 shares of the company's stock in a transaction that occurred on Friday, October 9th. The shares were sold at an…
3 weeks ago benzinga.com
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
A new NIH-backed initiative to speed up personalized cancer vaccine development sent stocks like MRNA, BNTX, and NVAX surging Friday.
-
3 weeks ago benzinga.com
Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $114
Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $115 to $114.
1 month ago benzinga.com
Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody
Invivyd reported Phase 3 LIBERTY trial data for VYD2311, showing strong safety and enhanced COVID-19 antibody levels.
1 month ago benzinga.com
Why Is BioNTech Stock Gaining Monday?
BioNTech (BNTX) Phase 3 data reveals gotistobart almost doubles survival in advanced lung cancer over standard docetaxel.
1 month ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 month ago benzinga.com
This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday
Analysts downgraded BioNTech, Gulfport Energy, Amgen and Best Buy; price targets fell for BioNTech and Gulfport.
1 month ago benzinga.com
Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings largely remain positive.
-
1 month ago benzinga.com
BMO Capital Downgrades BioNTech to Market Perform, Lowers Price Target to $105
BMO Capital analyst Evan Seigerman downgrades BioNTech (NASDAQ:BNTX) from Outperform to Market Perform and lowers the price target from $128 to $105.
-
2 months ago benzinga.com
Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $136
Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $142 to $136.
2 months ago benzinga.com
Take Two Interactive, Nvidia, Cheniere Energy And A Health Care Stock: CNBC’s ‘Final Trades’
Take-Two Interactive Software, on Aug. 7, reported adjusted earnings were 35 cents per share, topping the analyst consensus of 33 cents.
2 months ago benzinga.com
BioNTech Stock Dips After BNT122-01 Trial Termination
BioNTech shares are dropping Friday after the company decided to end its Phase 2 trial of autogene cevumeran in resected colorectal cancer.
2 months ago benzinga.com
QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax
FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligibility for adults 65+ and those with high-risk conditions.
-
2 months ago benzinga.com
FDA Approves Pfizer And BioNTech's Supplemental Biologics License Application For 2026-2027 COVID-19 Vaccine Formula
2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variantsShipping will begin immediately to ensure rapid access to…
2 months ago benzinga.com
Why Is Arbutus Biopharma Stock Gaining Friday?
Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auction. Get the offer details.
2 months ago benzinga.com
Merck and Moderna's Phase 3 Win Raises the Stakes for BioNTech and Roche (CORRECTED)
Merck & Moderna's partnership reports first Phase 3 success for personalized cancer vaccine, raising stakes for BioNTech & Genentech's program.
-
2 months ago benzinga.com
BioNTech Will Present New Data From Its Development Program in Lung Cancer Treatment at the IASLC 2026 World Conference on Lung Cancer In September; Data Highlights Progress Across Pumitamig (BNT327/BMS986545) and Gotistobart (BNT316/ONC-392), As Well As BioNTech’s mRNA-Based Immunotherapy Approaches
Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any PD-(L)1xVEGF bispecific immunomodulator combined with an antibody-drug conjugate, underscoring…
2 months ago benzinga.com
Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight
Healthcare stocks saw mixed after-hours moves, with Moderna and Merck cooling after explosive gains on positive cancer trial results.
2 months ago benzinga.com
Pfizer Stock Rises Wednesday: What's Going On?
Pfizer Inc (NYSE:PFE) shares are trading higher Wednesday, moving in sympathy with mRNA cancer vaccine-related companies after Merck & Co Inc (NYSE:MRK) and Moderna Inc (NASDAQ:MRNA) announced that…
2 months ago benzinga.com
Why Is BioNTech Stock Surging on Wednesday?
BioNTech stock rises as Merck and Moderna report positive cancer vaccine data, highlighting its individualized mRNA cancer therapies.
2 months ago benzinga.com
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday
Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.
-
2 months ago benzinga.com
Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVID-19, Influenza No Longer Recommended For All Children
https://youtu.be/H_RititNE8U
-
2 months ago benzinga.com
Citigroup Maintains Buy on BioNTech, Lowers Price Target to $125
Citigroup analyst Geoff Meacham maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $130 to $125.
-
2 months ago benzinga.com
Evercore ISI Group Maintains Outperform on BioNTech, Lowers Price Target to $130
Evercore ISI Group analyst Cory Kasimov maintains BioNTech (NASDAQ:BNTX) with a Outperform and lowers the price target from $135 to $130.